# Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Canonical URL: https://biopharmsignal.com/news/RVMD/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic-cancer
Ticker: RVMD
Company: Revolution Medicines
Source: Revolution Medicines
Published: 2026-04-13 12:00 EST
Original Source URL: https://ir.revmed.com
## Summary

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities REDWOOD CITY, Calif.,

## Article Body
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities REDWOOD CITY, Calif.,
## Recent Company News
- 2026-05-31 12:06 EST — [Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
- 2026-05-21 20:05 EST — [Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation](https://biopharmsignal.com/news/RVMD/revolution-medicines-to-host-investor-conference-call-on-positive-rasolute-302-results-following-2026-asco-presentation) — Source: Revolution Medicines
- 2026-05-06 22:00 EST — [Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-1-2-clinical-data-on-daraxonrasib-in-pancreatic-cancer) — Source: Revolution Medicines
- 2026-05-06 20:02 EST — [Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress](https://biopharmsignal.com/news/RVMD/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress) — Source: Revolution Medicines
- 2026-05-01 14:41 EST — [Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-statement-on-fda-expanded-access-authorization-for-daraxonrasib-in-patients-with-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)